Gaorong Capital Leads New Round In Chinese AI-Based Microbiome Drug Developer

Sophy Yang
June 24, 2019 — 15:41 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Artificial Intelligence big data biotech chinese Gaorong Capital guangdong gut microbiome healthcare investment medicine pharmaceutical shenzhen technology venture capital Xbiome

Related News:

Chinese AI Unicorn Zhipu AI Secures Major Funding Amid Competitive Landscape

September 19, 2024 — 01:18

ByteDance Expands AI Hardware Ambitions with Smart Headphones, AI Glasses, and More

September 14, 2024 — 01:59

Zhipu AI Unveils New Products and Announces Further Price Cuts as GenAI Price Wars Deepen in China

June 7, 2024 — 00:11

ByteDance Eyes AI Hardware, Exploring Wearable Earphones and Handheld AI Devices, Inspired by Microsoft’s Ecosystem Strategy

May 30, 2024 — 07:34

ByteDance’s Generative AI Play: Innovations vs. Pricing Wars – Will the App-Centric Strategy Prevail in the AI Era?

May 21, 2024 — 02:52

Decoding China’s Top Ten Generative AI Models: Established Tech Old Guards Lead the Charge in the GenAI Era

May 16, 2024 — 01:59

Hong Kong’s Bitcoin and Ethereum Spot ETFs Suffer Disappointing Debut, Yet Hope for Future Growth Persists

April 30, 2024 — 23:36

ByteDance’s Pragmatic AI Strategy: A Factor in Its Lag Behind OpenAI and Its Approach to Catching Up

April 24, 2024 — 00:28

Hong Kong Approves Spot Bitcoin and Ethereum ETFs, Enabling In-Kind Redemptions and Anticipated to Energize Local Crypto Market

April 16, 2024 — 03:57

Franchising and Licensing Asia (FLAsia) 2024